Abstract
Cardiovascular disease (CVD) is an important comorbidity in a number of chronic inflammatory diseases. However, evidence in highly prevalent respiratory disease such as asthma are still limited. Epidemiological and clinical data are not univocal in supporting the hypothesis that asthma and CVD are linked and the mechanisms of this relationship remain poorly defined. In this review, we explore the relationship between asthma and cardiovascular disease, with a specific focus on cytokine contribution to vascular dysfunction and atherosclerosis. This is important in the context of recent evidence linking broad inflammatory signaling to cardiovascular events. However inflammatory regulation in asthma is different to the one typically observed in atherosclerosis. We focus on the contribution of cytokine networks encompassing IL-4, IL-6, IL-9, IL-17A, IL-33 but also IFN-γ and TNF-α to vascular dysfunction in atherosclerosis. In doing so we highlight areas of unmet need and possible therapeutic implications.
Introduction
Cardiovascular disease (CVD) is the underlying cause of around 30% of deaths worldwide, approximately 80% of which stem from the underlying pathology of atherosclerosis causing the clinical manifestations of myocardial infarction (MI) and ischemic stroke (WHO, 2011). It is well established that inflammation and the immune system contribute to the development of atherosclerosis, along with various other cardiovascular disorders (Harrison et al., 2011; Hu et al., 2015; Welsh et al., 2017; MacRitchie et al., 2020). As a result, clinical research is now progressing in this area pioneered by the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial, the results of which were released in the last 2 years (Ridker et al., 2017). This trial found that pharmacological inhibition of cytokine interleukin-1β (IL-1β) with the monoclonal antibody Canakinumab significantly reduced subsequent cardiovascular events in people who had previously suffered a MI. Furthermore, patients which responded best to this treatment were those which had higher levels of circulating IL-6 and C-Reactive Protein (CRP), indicative of systemic inflammation (Maffia and Guzik, 2019). CANTOS trial has been followed by the CIRT trial (Cardiovascular Inflammation Reduction Trial), where treatment with low-dose methotrexate failed to lower cardiovascular event rates in patients with previous multivessel coronary artery disease or MI and affected by metabolic syndrome or type 2 diabetes (Ridker et al., 2019). These results confirmed that selective targeting of proinflammatory cytokines in atherosclerosis could be a beneficial addition to current treatments, which is dominated by cholesterol lowering drugs.
In light of the important role immune-inflammatory responses play in driving atherosclerosis it is unsurprising that patients suffering from chronic inflammatory diseases are more prone to CVD (Tseng et al., 2015; Liu C. et al., 2016; Czesnikiewicz-Guzik et al., 2019; Ferguson et al., 2019). However, the relationship between the highly prevalent disorder asthma, reported to affect around 10–25% of the population of Europe and more than 200 million people world-wide (https://ginasthma.org/), and CVD still needs to be fully elucidated. As such, further research in the area is strongly required, given that asthmatic patients may represent a large group of people at greater risk for developing CVD, a clinical burden which is not currently addressed (To et al., 2012; Strand et al., 2018).
The release of cytokines is central to almost every stage of the immune response in asthma, and consequent systemic dysregulation of inflammatory homeostasis may explain their potential higher risk of developing CVD. It may be plausible that targeting cytokines which are both highly expressed in asthma and causative in cardiovascular pathology may represent a pharmacological strategy for the treatment of accelerated CVD in asthma. Therefore, in this mini review, we will explore CVD comorbidity in asthma, and we will discuss whether cytokines may be potential pharmacological targets at the interface of these two disorders (Figure 1).
Figure 1
Asthma Pathology and Cardiovascular Comorbidity
Asthma is a heterogeneous disease widely understood to be associated with airway hyperresponsiveness and inflammation. Pathological obstruction due to mucus production and structural changes in the airways, due to epithelium thickening and abnormal accumulation of airway smooth muscle cells, reduces airways caliber to generate the characteristic asthmatic symptoms (shortness of breath, coughing or wheezing, chest tightness or pain) (Holgate et al., 1999). The best known phenotype of asthma is allergic asthma, in which these symptoms are caused by inhaled allergens such as house dust mites, animal dander, fungi, and pollens (Kudo et al., 2013), triggering an immunological response driven by T helper type 2 (Th2) cells and their associated cytokines IL-4, IL-5, and IL-13 (Lloyd and Hessel, 2010). However, alternative inflammatory and non-inflammatory mechanisms for asthma have been described and it is now accepted that there are multiple phenotypes and endotypes of the pathology (Bossley et al., 2012; Fahy, 2015). Whether these distinctions confer susceptibility or protection from developing CVD remains unclear.
Asthma and atherosclerosis are both characterized by accumulation of immune cells at the site of injury, increased tissue and circulating levels of IgE, and activation of mast cells and smooth muscle cells (Willems et al., 2013; Liu C. et al., 2016). Asthma is also characterized by an elevation of circulating proinflammatory and Th2 cytokines, indicating that the vasculature is systemically exposed to the inflammation generated in the lungs (Wong et al., 2001; Huang et al., 2016; Zhu et al., 2016). Therefore, patients with asthma are exposed to an inflammatory environment that may favor atherosclerosis progression, even though, clinical data are not univocal in supporting this hypothesis.
A prospective cohort study of 446,346 Taiwanese adults showed that active asthma is associated with adverse cardiovascular consequences (Strand et al., 2018). Atherosclerosis Risk in Communities (ARIC), a prospective study on the etiology of atherosclerotic-related diseases, demonstrated an association with increased carotid artery intima–media thickness (IMT) (Onufrak et al., 2007) and incidence of coronary heart disease (CHD) and stroke (Onufrak et al., 2008) in women with late-onset asthma, but not in those with child-onset asthma. Similar studies have also reached the conclusion that late-onset asthma inferred a greater risk of CVD (Lee et al., 2012; Tattersall et al., 2016). It was speculated that this may be due to the large overlap between the risk factors between late-onset asthma and CVD, few of which are linked to inflammation such as obesity, stress, estrogen-modulated inflammation, and increased numbers of eosinophils (Wenzel, 2012). Other studies confirmed that both asthma and allergy were independently associated with an increased risk of CHD (Iribarren, 2004; Kim et al., 2010; Iribarren et al., 2012), that asthma led to augmented vascular inflammation (Vijayakumar et al., 2013), and that patients with allergic rhinitis and asthma or chronic rhinosinusitis showed an increase of carotid IMT (Knoflach et al., 2005; Elcioglu et al., 2016). One study has shown there is a significant decrease in endothelium dependent vasodilatation in asthmatic patients (Yildiz et al., 2004), while other studies found they had significantly increased arterial stiffness (Augusto et al., 2017; Tuleta et al., 2017). Both are prognostic factors which are independent predictors of cardiovascular events. Interestingly, the latter study also included young asthmatic patients, suggesting that the biological mechanisms pertaining to cardiovascular comorbidity in asthma may also be present in childhood.
On the contrary, a large study investigating the association of self-reported, doctor diagnosed asthma and CVD in adults followed over 14 years, showed that asthma and duration of asthma did not associate with CHD (Schanen, 2005). Similarly, patients with allergic rhinitis had lower incidence of acute MI and cerebrovascular disease in a large retrospective, population-based, matched cohort study (Yoon et al., 2016); while another study investigating 61,899 Taiwanese patients affected by rhinitis and 123,798 age- and sex-matched controls, found they had decreased risk of developing acute ischemic stroke (Tseng et al., 2015). In summary, clinical and epidemiological data so far are unresolved.
A confounding factor to be considered may be the long-term use of asthmatic medication on the cardiovascular system. For example, one large cohort study demonstrated that only asthma patients using medications (particularly those on oral corticosteroids alone or in combination) were at a greater risk of developing CVD (Iribarren et al., 2012). On the contrary, a combination of inhaled corticosteroid and long-acting β2-agonist approved for the treatment of chronic obstructive pulmonary disease (COPD) and asthma led to improved lung function in subjects with COPD and comorbid CVD, without increasing CVD risk (Covelli et al., 2016). Consequently, further examination into the specific pathways which may be modulated by chronic use of anti-asthmatic drugs should be explored in relation to how they may contribute to the development of CVD.
A final consideration should be given to cigarette smoking, a major risk factor for CVD (GBD 2015 Risk Factors Collaborators, 2016). Compared with never-smokers with asthma, asthma patients who smoke have worse symptoms, increased chronic mucus hypersecretion, and more exacerbations, as well as an impaired therapeutic response to corticosteroids and a different inflammatory profile in sputum and blood (Thomson et al., 2013). Smokers with asthma have higher rates of cardiovascular comorbidities (Çolak et al., 2015). The endotype of smokers with asthma is more pro-inflammatory than the Th2 phenotype typically associated with atopic asthma (Peters et al., 2014; Fahy, 2015; Lambrecht et al., 2019). This pro-inflammatory phenotype may lead to increased CVD risk. Statins, which exert pleiotropic anti-inflammatory effects, reduced frequency of heart failure in the asthma–COPD overlap syndrome (Yeh et al., 2019), suggesting that a comparative study will be informative of communal mechanisms leading to exacerbated CVD and asthma in smokers.
In addition to controversial clinical observations linking asthma to atherosclerosis, there is also insufficient basic research in this area. One study which did explore this relationship yielded very interesting results when utilizing the ovalbumin (OVA)-alum sensitization/challenge model of allergic pulmonary inflammation in atherosclerotic apolipoprotein-E (apoE)−/− mice. In fact, asthmatic apoE−/− mice were found to have significantly larger and more vulnerable plaques compared to PBS-challenged apoE−/− shams (Wang et al., 2014). This was attributed to elevated circulating Th2 and Th17 cells, along with their associated cytokines IL-4 and IL-17A respectively, at both early and advanced stages of pathology in the apoE−/− mice with asthma. The group then assessed if suppressing the increased serum levels of IL-4 and IL-17A, using neutralizing antibodies, could attenuate disease progression in these mice. Remarkably, lesion size was reduced by inhibition of either IL-4 or IL-17A individually, but with an even greater effect observed when both were targeted in combination. Another study demonstrated that both chronic and acute allergic lung inflammation, induced in mice by ovalbumin sensitization and challenge, promoted atheroma formation, regardless whether lung inflammation occurred before, after, or at the same time as atherogenesis (Liu C.L. et al., 2016). Therefore these studies not only may support clinical data in finding that atherosclerosis pathology is exacerbated by asthma, but also proposes a potential method for clinical intervention, through targeting the proinflammatory cytokines which act at the interface of these two pathologies (Wang et al., 2014). However, it should be considered that the OVA-alum protocol, while useful for modeling asthmatic features and symptoms in mice, is likely not to be completely reflective of the complex and heterogeneous human disease (Aun et al., 2017). Consequently, further studies of this nature are required to fully elucidate the mechanisms and key players underpinning the potential accelerated development of atherosclerosis in asthma.
Targeting Cytokines
As discussed previously, the CANTOS trial has demonstrated that targeting pro-inflammatory cytokines highly expressed in CVD can significantly improve clinical outcomes in patients (Ridker et al., 2017). Here we will discuss the cytokines of asthma which act to disrupt inflammatory homeostasis and consequently may exacerbate the progression of CVD.
The CANTOS trial utilized a monoclonal antibody to inhibit the multifunctional pro-inflammatory cytokine IL-1β, often referred to as the gatekeeper of inflammation due to its ability to regulate numerous immune cascades (Libby, 2017; Panahi et al., 2018). It is therefore unsurprising that IL-1β and some of its downstream targets have been implicated in asthma, particularly in the more severe forms of the disorder (Kim et al., 2017; Lambrecht et al., 2019).
IL-1β is activated by the caspase-1/NLRP3 inflammasome signaling which has been demonstrated to be causative in pathogenesis in two different OVA-mediated murine models of allergic pulmonary inflammation (Besnard et al., 2011; Kim et al., 2017). Deficiency in NLRP3 or IL-1R1 in mice which were subjected to airway sensitization and challenge of OVA significantly reduced cell infiltration and mucus production in the lung (Besnard et al., 2011). This model was performed without the use of aluminum adjuvant in order to better reflect naturally occurring disease, and the result determined to be due to a loss of the Th2 inflammatory allergic response (IL-5, IL-13, IL-33) which is classically associated with asthma. Similarly, Kim et al. utilized a model of severe steroid-resistant asthma (SSRA) and found that pharmacological inhibition of different members of the NLRP3 inflammasome signaling pathway suppressed the cardinal features of SSRA (Kim et al., 2017). In humans, both IL-1 receptor and NLRP3 inflammasome are elevated in the sputum of non-smoking adults with asthma (Simpson et al., 2014; Evans et al., 2018). These findings paired with the recent success of the CANTOS trial supports the notion that the NLRP3-IL-1β axis may be an appealing area for further investigation into a targetable link between asthma pathology and the development of CVD.
IL-33, another member of the IL-1 family, is found to be significantly increased in the serum of asthmatic patients (Momen et al., 2017; Ding et al., 2018). IL-33 functions as an “alarmin” which is released by the lung epithelial cells following stress or damage-induced necrosis, once released IL-33 promotes activation of the Th2-branch of the immune response (Robinson et al., 1992). Efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) is currently under investigation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) (ClinicalTrials.gov Identifier: NCT03546907). However, the role of IL-33 in cardiovascular disease is controversial. While a few reports have shown that IL-33 induced endothelial cell activation and increased angiogenesis and vascular permeability, in contrast, others have demonstrated that treatment with IL-33 reduced experimental atherosclerosis (Miller et al., 2008; Choi et al., 2009; Aoki et al., 2010; Demyanets et al., 2011; Altara et al., 2018).
The predominance of the Th2 response in asthma has traditionally sparked controversy in relation to its association with atherosclerosis-related CVD, classically Th1-dominated pathologies. For example, IL-13, a prototypical Th2 cytokine, has been shown to protect from experimental atherosclerosis through the induction of alternatively activated macrophages (Cardilo-Reis et al., 2012). However, there is evidence that Th2 cytokines may also play a detrimental role in the CVD (Liu C. et al., 2016; Niccoli et al., 2018). Importantly, in the combined murine model described by Wang et al. expression and production of IL-4 was increased in the apoE−/− mice after they were subject to allergic pulmonary inflammation, which was demonstrated to be partially causative in increasing plaque size and vulnerability (Wang et al., 2014). IL-4 is an important therapeutic target in asthma. The alpha subunit of the IL-4 receptor (dupilumab), that blocks both IL-4 and IL-13 pathways, has resulted in reduction of asthma morbidity, while the use of the anti-IL-4R failed in phase II (Eger and Bel, 2019). Mechanistically, IL-4 has been shown to increase endothelial permeability and dysfunction via cytoskeleton remodeling (Skaria et al., 2016). In addition, IL-4 can influence the activity of pro-inflammatory IL-6, resulting in exacerbation of the immune response via CD4+ T cell activation and inflammatory endothelium dysfunction (Rincón et al., 1997; Lee et al., 2010).
Upon exposure to several environmental antigens which trigger the Th2 response, IL-9 is also released and overexpression can lead to inflammation and airway hyperresponsiveness (Zhou et al., 2001). Elevated levels of IL-9 are observed in the sputum of asthmatic patients and expression in the nasal mucosa has been observed to increase in response to seasonal allergen changes (Zhou et al., 2001; Nouri-Aria et al., 2005; Lloyd and Hessel, 2010). However, the first randomized controlled trial to evaluate the effect of an anti-IL-9 monoclonal antibody showed no effect in adults with uncontrolled asthma (Oh et al., 2013). High levels of systemic IL-9 have been demonstrated to influence also atherosclerotic pathology, wherein administration of recombinant IL-9 in apoE−/− mice enhanced inflammatory cell infiltration into lesions via modulation of VCAM-1 expression, resulting in enlarged plaques (Zhang et al., 2015).
Th1 and Th17- type responses have also been shown to play a role in asthma pathogenesis, and elevated levels of IFN-γ, TNF-α, and IL-17A can be found in the serum of asthmatic patients. This is of particular interest as Th1 and Th17 type responses are more characteristically associated with atherosclerosis (Sage and Mallat, 2017). It should be noted, however, that several of these mediators have also been shown to be produced by mast cells in asthma (Kennedy et al., 2013).
The pleiotropic IL-6 is expressed at high levels in asthma (Rincon and Irvin, 2012). Interestingly, IL-6 can translocate from inflamed lung to the systemic circulation in mice, and was also found to be elevated in the sputum of some patients with mild to moderate asthma (Neveu et al., 2010; Kido et al., 2011). These higher levels of IL-6 may contribute to driving CVD comorbidity in asthma. Interestingly, genetic variants which lead to higher circulating concentrations of IL-6 receptor (neutralizing IL-6 cell signaling) appear protective against CHD (Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium et al., 2012). Interestingly, IL-6 trans-signaling is associated to risk of future cardiovascular events (Ziegler et al., 2019) and recently, epithelial IL-6 trans-signaling has been shown to define a new asthma phenotype with increased airway inflammation (Jevnikar et al., 2019). In experimental atherosclerosis, IL-6 mRNA expression was found in the atherosclerotic plaques of apoE−/− mice (Sukovich et al., 1998). Further to this, the balance between IL-6 and anti-inflammatory IL-10 is believed to influence lipid homeostasis, plaque formation, and plaque morphology in mice (Schieffer et al., 2004). IL-6 is also well associated with abdominal aortic aneurysm (AAA) pathogenesis, primarily through modulating cell migration and infiltration (Nishihara et al., 2017). To date, however, IL-6 targeting has not been tested in secondary prevention of atherosclerosis and a phase 2a study, designed to evaluate the effects of sirukumab (human anti IL-6 monoclonal antibody) in subjects with severe poorly controlled asthma, was withdrawn (ClinicalTrials.gov Identifier: NCT02794519). In a recent small proof-of-concept clinical trial, a single dose of tocilizumab (IL-6 receptor blocker) was unable to prevent allergen-induced bronchoconstriction (Revez et al., 2019) (Australian New Zealand Clinical Trials Registry: ACTRN12614000123640).
Tumor necrosis factor-α (TNF-α), another cytokine implicated in both asthma and cardiovascular disease, at first appears to be a promising target for further research in targeting shared dysregulation in these two pathologies (Brightling et al., 2008; Welsh et al., 2017). Pharmacological inhibition of TNF-α activity with the monoclonal antibody infliximab, suppressed IL-4 production, adhesion molecule expression, and eosinophil infiltration in a mouse experimental model of allergic rhinitis, the pathology of which is similar to asthma (Mo et al., 2011). However, initial clinical trials performed to test this drug in asthma yielded underwhelming results, with no clinical benefits observed (Edwards and Polosa, 2007; Matera et al., 2010). On the contrary, etanercept, in a small cohort of 39 patients with severe corticosteroid refractory asthma, caused a small but significant improvement in asthma control (Morjaria et al., 2008) but using golimumab there was no favorable risk–benefit profile in patients with severe persistent asthma (Wenzel et al., 2009). No clear efficacy of anti-TNF treatments has been shown to date in CVD. One of the main limitations, is the fact that randomized controlled trials in chronic inflammatory diseases have been powered to demonstrate improvements in disease activity rather than in CVD endpoints (Welsh et al., 2017). However, meta-analysis of observational studies in patients affected by chronic inflammation suggest that those receiving TNF-α blockers are at lower risk of CVD (Roubille et al., 2015). More recently, the ENTRACE trial results demonstrated cardiovascular safety of tocilizumab (IL-6 receptor blocker) and etanercept (TNF-α blocker) in rheumatoid arthritis patients. Assessment of clinical efficacy, however, will require the enrolment of a much larger sample size (Giles et al., 2019).
In asthmatic hyperlipidemic apoE−/− mice, T-regulatory cells (Tregs) were found to be decreased in the early stages of the pathology (Wang et al., 2014). Over the last decade, the anti-inflammatory cytokine IL-10, mainly produced by Tregs, has been under the spotlight in regards to its role in a variety of allergic diseases (Hawrylowicz, 2005). IL-10 is expressed on epithelial and endothelial cells of nasal mucosa in patients affected by allergic rhinitis and IL-10 serum levels are observed to be significantly lower in asthmatic patients compared to healthy controls (Muller et al., 2014; Raeiszadeh Jahromi et al., 2014). It is believed that enhancing IL-10 activity in allergic diseases such as asthma could be beneficial to pathology, and in CVD there is evidence that also supports this hypothesis. IL-10 deficiency significantly augments the development of atherosclerotic lesions in hyperlipidemic low-density lipoprotein receptor (LdlR)−/− mice and also accelerates neointimal formation in hypercholesteremic ApoE*3-Liden mice (Potteaux et al., 2004; Eefting et al., 2007). Similarly, Tregs have been shown to be clearly protective in experimental atherosclerosis (Sage and Mallat, 2017), and two clinical trials are currently investigating the possibility to promote Treg expansion in patients with small abdominal aortic aneurysms (VIVAAA; ClinicalTrials.gov Identifier: NCT02846883), or with stable ischemic heart disease and acute coronary syndromes (LILACS; ClinicalTrials.gov Identifier: NCT03113773).
Another anti-inflammatory cytokine IL-37 expression was significantly reduced in the sputum of asthmatic children (Charrad et al., 2016), and was shown to be a key suppressor of asthma mediated mast cells (Conti et al., 2017) and airway inflammation and remodeling (Huang et al., 2018; Meng et al., 2019). IL-37 has also been found to exert athero-protective effects via the modulation of dendritic cell maturation, macrophage activation and by inducing Treg responses (Chai et al., 2015; Ji et al., 2017; McCurdy et al., 2017; Liu et al., 2018). Enhancing the activity of anti-inflammatory cytokines such as IL-10 and IL-37, which have protective roles in both disease states could be another potential avenue for pharmacological intervention for asthmatic patients who develop or are at high risk for developing CVD as a comorbidity.
Conclusion
To date the clinical evidence supporting the hypothesis that asthma confers high risk of various cardiovascular pathologies to patients is not univocal, and the specific biological mechanisms which may facilitate the development of cardiovascular comorbidity remain to be fully determined for potential pharmacological intervention to be explored. As inflammation plays a pivotal role in both atherosclerosis and asthma, potential targets for this research are cytokines whose dysregulation have notable effects in both diseases.
Funding
Our work is supported by the British Heart Foundation (BHF) grants PG/12/81/29897, RE/13/5/30177, FS/16/55/32731, and PG/19/84/34771; the Engineering and Physical Sciences Research Council (EPSRC) grant EP/L014165/1; the European Commission Marie Skłodowska-Curie Individual Fellowships 661369 and the European Research Council (Project Identifier: 726318).
Statements
Author contributions
DG and LM equally contributed to the writing of the manuscript. CM, TG, and PM revised and finalized the text. All authors have read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AltaraR.GhaliR.MallatZ.CataliottiA.BoozG. W.ZoueinF. A. (2018). Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc. Res.114, 1578–1594. doi: 10.1093/cvr/cvy166
2
AokiS.HayakawaM.OzakiH.TakezakoN.ObataH.IbarakiN.et al. (2010). ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol. Cell Biochem.335, 75–81. doi: 10.1007/s11010-009-0244-9
3
AugustoL. S.SilvaG. C.PinhoJ. F.AiresR. D.LemosV. S.RamalhoL. F. C.et al. (2017). Vascular function in asthmatic children and adolescents. Respir. Res.18, 17. doi: 10.1186/s12931-016-0488-3
4
AunM. V.Bonamichi-SantosR.Arantes-CostaF. M.KalilJ.Giavina-BianchiP. (2017). Animal models of asthma: utility and limitations. J. Asthma Allergy10, 293–301. doi: 10.2147/JAA.S121092
5
BesnardA.-G.GuillouN.TschoppJ.ErardF.CouillinI.IwakuraY.et al. (2011). NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy66, 1047–1057. doi: 10.1111/j.1398-9995.2011.02586.x
6
BossleyC. J.FlemingL.GuptaA.RegameyN.FrithJ.OatesT.et al. (2012). Pediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokines. J. Allergy Clin. Immunol.129, 974–982.e13. doi: 10.1016/j.jaci.2012.01.059
7
BrightlingC.BerryM.AmraniY. (2008). Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol.121, 5–10. doi: 10.1016/j.jaci.2007.10.028
8
Cardilo-ReisL.GruberS.SchreierS. M.DrechslerM.Papac-MilicevicN.WeberC.et al. (2012). Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol. Med.4, 1072–1086. doi: 10.1002/emmm.201201374
9
ChaiM.JiQ.ZhangH.ZhouY.YangQ.ZhouY.et al. (2015). The protective effect of interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein E-deficient mice with diabetes. J. Interferon. Cytokine Res. Off. J. Int. Soc. Interferon. Cytokine Res.35, 530–539. doi: 10.1089/jir.2014.0212
10
CharradR.BerraïesA.HamdiB.AmmarJ.HamzaouiK.HamzaouiA. (2016). Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-17A. Immunobiology221, 182–187. doi: 10.1016/j.imbio.2015.09.009
11
ChoiY.-S.ChoiH.-J.MinJ.-K.PyunB.-J.MaengY.-S.ParkH.et al. (2009). Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood114, 3117–3126. doi: 10.1182/blood-2009-02-203372
12
ÇolakY.AfzalS.NordestgaardB. G.LangeP. (2015). Characteristics and prognosis of never-smokers and smokers with asthma in the Copenhagen general population study. a prospective cohort study. Am. J. Respir. Crit. Care Med.192, 172–181. doi: 10.1164/rccm.201502-0302OC
13
ContiP.RonconiG.CaraffaA.LessianiG.DuraisamyK. (2017). IL-37 a new IL-1 family member emerges as a key suppressor of asthma mediated by mast cells. Immunol. Invest.46, 239–250. doi: 10.1080/08820139.2016.1250220
14
CovelliH.PekB.SchenkenbergerI.Scott-WilsonC.EmmettA.CrimC. (2016). Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. Int. J. Chron. Obstruct. Pulmon. Dis.11, 1–12. doi: 10.2147/COPD.S91407
15
Czesnikiewicz-GuzikM.OsmendaG.SiedlinskiM.NosalskiR.PelkaP.NowakowskiD.et al. (2019). Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. Eur. Heart J. 40, 3459–3470 doi: 10.1093/eurheartj/ehz646
16
DemyanetsS.KonyaV.KastlS. P.KaunC.RauscherS.NiessnerA.et al. (2011). Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol.31, 2080–2089. doi: 10.1161/ATVBAHA.111.231431
17
DingW.ZouG.-L.ZhangW.LaiX.-N.ChenH.-W.XiongL.-X. (2018). Interleukin-33: its emerging role in allergic diseases. Mol. J. Synth. Chem. Nat. Prod. Chem.23, E1665. doi: 10.3390/molecules23071665
18
EdwardsC. J.PolosaR. (2007). Study of infliximab treatment in asthma. Am. J. Respir. Crit. Care Med.175, 196–196. doi: 10.1164/ajrccm.175.2.196
19
EeftingD.SchepersA.De VriesM. R.PiresN. M. M.GrimbergenJ. M.LagerweijT.et al. (2007). The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis193, 335–342. doi: 10.1016/j.atherosclerosis.2006.09.032
20
EgerK. A.BelE. H. (2019). The emergence of new biologics for severe asthma. Curr. Opin. Pharmacol.46, 108–115. doi: 10.1016/j.coph.2019.05.005
21
ElciogluO. C.AfsarB.BakanA.TakirM.OzkokA.OralA.et al. (2016). Chronic rhinosinusitis, endothelial dysfunction, and atherosclerosis. Am. J. Rhinol. Allergy30, e58–e61. doi: 10.2500/ajra.2016.30.4325
22
EvansM. D.EsnaultS.DenlingerL. C.JarjourN. N. (2018). Sputum cell IL-1 receptor expression level is a marker of airway neutrophilia and airflow obstruction in asthmatic patients. J. Allergy Clin. Immunol.142, 415–423. doi: 10.1016/j.jaci.2017.09.035
23
FahyJ. V. (2015). Type 2 inflammation in asthma—present in most, absent in many. Nat. Rev. Immunol.15, 57–65. doi: 10.1038/nri3786
24
FergusonL. D.SiebertS.McInnesI. B.SattarN. (2019). Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat. Rev. Rheumatol.15, 461–474. doi: 10.1038/s41584-019-0256-0
25
GBD 2015 Risk Factors Collaborators (2016). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond. Engl.388, 1659–1724. doi: 10.1016/S0140-6736(16)31679-8
26
GilesJ. T.SattarN.GabrielS.RidkerP. M.GayS.WarneC.et al. (2019). Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. Hoboken NJ. 72, 31–40 doi: 10.1002/art.41095
27
HarrisonD. G.GuzikT. J.LobH.MadhurM.MarvarP. J.ThabetS.et al. (2011). Inflammation, immunity and hypertension. Hypertension57, 132–140. doi: 10.1161/HYPERTENSIONAHA.110.163576
28
HawrylowiczC. M. (2005). Regulatory T cells and IL-10 in allergic inflammation. J. Exp. Med.202, 1459–1463. doi: 10.1084/jem.20052211
29
HolgateS. T.LackieP. M.DaviesD. E.RocheW. R.WallsA. F. (1999). The bronchial epithelium as a key regulator of airway inflammation and remodelling in asthma. Clin. Exp. Allergy29, 90–95. doi: 10.1046/j.1365-2222.1999.00016.x
30
HuD.MohantaS. K.YinC.PengL.MaZ.SrikakulapuP.et al. (2015). Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin β receptors. Immunity42, 1100–1115. doi: 10.1016/j.immuni.2015.05.015
31
HuangA.-X.LuL.-W.LiuW.-J.HuangM. (2016). Plasma inflammatory cytokine IL-4, IL-8, IL-10, and TNF-α levels correlate with pulmonary function in patients with asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.22, 2800–2808. doi: 10.12659/MSM.896458
32
HuangN.LiuK.LiuJ.GaoX.ZengZ.ZhangY.et al. (2018). Interleukin-37 alleviates airway inflammation and remodeling in asthma via inhibiting the activation of NF-κB and STAT3 signalings. Int. Immunopharmacol.55, 198–204. doi: 10.1016/j.intimp.2017.12.010
33
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumSwerdlowD. I.HolmesM. V.KuchenbaeckerK. B.EngmannJ. E. L.ShahT.et al. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet Lond. Engl.379, 1214–1224. doi: 10.1016/S0140-6736(12)60110-X
34
IribarrenC.TolstykhI. V.MillerM. K.SobelE.EisnerM. D. (2012). Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am. J. Epidemiol.176, 1014–1024. doi: 10.1093/aje/kws181
35
IribarrenC. (2004). Are patients with asthma at increased risk of coronary heart disease? Int. J. Epidemiol.33, 743–748. doi: 10.1093/ije/dyh081
36
JevnikarZ.ÖstlingJ.AxE.CalvénJ.ThörnK.IsraelssonE.et al. (2019). Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. J. Allergy Clin. Immunol.143, 577–590. doi: 10.1016/j.jaci.2018.05.026
37
JiQ.MengK.YuK.HuangS.HuangY.MinX.et al. (2017). Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice. Sci. Rep.7, 1–13. doi: 10.1038/s41598-017-02987-4
38
KennedyS.WuJ.WadsworthR. M.LawrenceC. E.MaffiaP. (2013). Mast cells and vascular diseases. Pharmacol. Ther.138, 53–65. doi: 10.1016/j.pharmthera.2013.01.001
39
KidoT.TamagawaE.BaiN.SudaK.YangH.-H. C.LiY.et al. (2011). Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am. J. Respir. Cell Mol. Biol.44, 197–204. doi: 10.1165/rcmb.2009-0427OC
40
KimJ.PurushottamB.ChaeY. K.ChebroluL.AmanullahA. (2010). Relation between common allergic symptoms and coronary heart disease among NHANES III participants. Am. J. Cardiol.106, 984–987. doi: 10.1016/j.amjcard.2010.05.029
41
KimR. Y.PinkertonJ. W.EssilfieA. T.RobertsonA. A. B.BainesK. J.BrownA. C.et al. (2017). Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma. Am. J. Respir. Crit. Care Med.196, 283–297. doi: 10.1164/rccm.201609-1830OC
42
KnoflachM.KiechlS.MayrA.WilleitJ.PoeweW.WickG. (2005). Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. Arch. Intern. Med.165, 2521. doi: 10.1001/archinte.165.21.2521
43
KudoM.IshigatsuboY.AokiI. (2013). Pathology of asthma. Front. Microbiol.4, 263. doi: 10.3389/fmicb.2013.00263
44
LambrechtB. N.HammadH.FahyJ. V. (2019). The cytokines of asthma. Immunity50, 975–991. doi: 10.1016/j.immuni.2019.03.018
45
LeeY. W.LeeW. H.KimP. H. (2010). Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium. Cytokine49, 73–79. doi: 10.1016/j.cyto.2009.08.009
46
LeeH. M.TruongS. T.WongN. D. (2012). Association of adult-onset asthma with specific cardiovascular conditions. Respir. Med.106, 948–953. doi: 10.1016/j.rmed.2012.02.017
47
LibbyP. (2017). Interleukin-1 beta as a target for atherosclerosis therapy: the biological basis of CANTOS and beyond. J. Am. Coll. Cardiol.70, 2278–2289. doi: 10.1016/j.jacc.2017.09.028
48
LiuC.ZhangJ.ShiG.-P. (2016). Interaction between allergic asthma and atherosclerosis. Transl. Res. J. Lab. Clin. Med.174, 5–22. doi: 10.1016/j.trsl.2015.09.009
49
LiuC.-L.WangY.LiaoM.SantosM. M.FernandesC.SukhovaG. K.et al. (2016). Allergic lung inflammation promotes atherosclerosis in apolipoprotein E-deficient mice. Transl. Res. J. Lab. Clin. Med.171, 1–16. doi: 10.1016/j.trsl.2016.01.008
50
LiuJ.LinJ.HeS.WuC.WangB.LiuJ.et al. (2018). Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability. Cell Physiol. Biochem. Int. J. Exp. Cell Physiol. Biochem. Pharmacol.45, 1034–1050. doi: 10.1159/000487344
51
LloydC. M.HesselE. M. (2010). Functions of T cells in asthma: more than just TH2 cells. Nat. Rev. Immunol.10, 838–848. doi: 10.1038/nri2870
52
MacRitchieN.GrassiaG.NoonanJ.ColeJ. E.HughesC. E.SchroederJ.et al. (2020). The aorta can act as a site of naïve CD4+ T-cell priming. Cardiovasc. Res. 116, 306–316 doi: 10.1093/cvr/cvz102
53
MaffiaP.GuzikT. J. (2019). When, where, and how to target vascular inflammation in the post-CANTOS era? Eur. Heart J.40, 2492–2494. doi: 10.1093/eurheartj/ehz133
54
MateraM. G.CalzettaL.CazzolaM. (2010). TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm. Pharmacol. Ther.23, 121–128. doi: 10.1016/j.pupt.2009.10.007
55
McCurdyS.BaumerY.ToulminE.LeeB.-H.BoisvertW. A. (2017). Macrophage-specific expression of IL-37 in hyperlipidemic mice attenuates atherosclerosis. J. Immunol.199, 3604–3613. doi: 10.4049/jimmunol.1601907
56
MengP.ChenZ.-G.ZhangT.-T.LiangZ.-Z.ZouX.-L.YangH.-L.et al. (2019). IL-37 alleviates house dust mite-induced chronic allergic asthma by targeting TSLP through the NF-κB and ERK1/2 signaling pathways. Immunol. Cell Biol.97, 403–415. doi: 10.1111/imcb.12223
57
MillerA. M.XuD.AsquithD. L.DenbyL.LiY.SattarN.et al. (2008). IL-33 reduces the development of atherosclerosis. J. Exp. Med.205, 339–346. doi: 10.1084/jem.20071868
58
MoJ.-H.KangE.-K.QuanS.-H.RheeC.-S.LeeC. H.KimD.-Y. (2011). Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model. Allergy. 66, 279–286 doi: 10.1111/j.1398-9995.2010.02476.x
59
MomenT.AhanchianH.ReisiM.ShamsdinS. A.ShahsanaiA.KeivanfarM. (2017). Comparison of interleukin-33 serum levels in asthmatic patients with a control group and relation with the severity of the disease. Int. J. Prev. Med.8, 65. doi: 10.4103/ijpvm.IJPVM_179_16
60
MorjariaJ. B.ChauhanA. J.BabuK. S.PolosaR.DaviesD. E.HolgateS. T. (2008). The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax63, 584–591. doi: 10.1136/thx.2007.086314
61
MullerB.van EgmondD.de GrootE. J.FokkensW. J.van DrunenC. M. (2014). Characterisation of interleukin-10 expression on different vascular structures in allergic nasal mucosa. Clin. Transl. Allergy4, 2. doi: 10.1186/2045-7022-4-2
62
NeveuW. A.AllardJ. L.RaymondD. M.BourassaL. M.BurnsS. M.BunnJ. Y.et al. (2010). Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir. Res.11, 28. doi: 10.1186/1465-9921-11-28
63
NiccoliG.MontoneR. A.SabatoV.CreaF. (2018). Role of allergic inflammatory cells in coronary artery disease. Circulation138, 1736–1748. doi: 10.1161/CIRCULATIONAHA.118.035400
64
NishiharaM.AokiH.OhnoS.FurushoA.HirakataS.NishidaN.et al. (2017). The role of IL-6 in pathogenesis of abdominal aortic aneurysm in mice. PloS One12, e0185923. doi: 10.1371/journal.pone.0185923
65
Nouri-AriaK. T.PiletteC.JacobsonM. R.WatanabeH.DurhamS. R. (2005). IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J. Allergy Clin. Immunol.116, 73–79. doi: 10.1016/j.jaci.2005.03.011
66
OhC. K.LeighR.McLaurinK. K.KimK.HultquistM. (2013). Molfino NA. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir. Res.14, 93. doi: 10.1186/1465-9921-14-93
67
OnufrakS.AbramsonJ.VaccarinoV. (2007). Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study. Atherosclerosis195, 129–137. doi: 10.1016/j.atherosclerosis.2006.09.004
68
OnufrakS. J.AbramsonJ. L.AustinH. D.HolguinF.McClellanW. M.VaccarinoL. V. (2008). Relation of adult-onset asthma to coronary heart disease and stroke. Am. J. Cardiol.101, 1247–1252. doi: 10.1016/j.amjcard.2007.12.024
69
PanahiM.PapanikolaouA.TorabiA.ZhangJ.-G.KhanH.VazirA.et al. (2018). Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovasc. Res.114, 1445–1461. doi: 10.1093/cvr/cvy145
70
PetersM. C.MekonnenZ. K.YuanS.BhaktaN. R.WoodruffP. G.FahyJ. V. (2014). Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J. Allergy Clin. Immunol.133, 388–394. doi: 10.1016/j.jaci.2013.07.036
71
PotteauxS.EspositoB.van OostromO.BrunV.ArdouinP.GrouxH.et al. (2004). Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol.24, 1474–1478. doi: 10.1161/01.ATV.0000134378.86443.cd
72
Raeiszadeh JahromiS.MaheshP. A.JayarajB. S.MadhunapantulaS. R. V.HollaA. D.VishweswaraiahS.et al. (2014). Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case–control study. J. Asthma51, 1004–1013. doi: 10.3109/02770903.2014.938353
73
RevezJ. A.BainL. M.WatsonR. M.TowersM.CollinsT.KillianK. J.et al. (2019). Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics. Clin. Transl. Immunol.8, e1044. doi: 10.1002/cti2.1044
74
RidkerP. M.EverettB. M.ThurenT.MacFadyenJ. G.ChangW. H.BallantyneC.et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med.377, 1119–1131. doi: 10.1056/NEJMoa1707914
75
RidkerP. M.EverettB. M.PradhanA.MacFadyenJ. G.SolomonD. H.ZaharrisE.et al. (2019). Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med.380, 752–762. doi: 10.1056/NEJMoa1809798
76
RincónM.AnguitaJ.NakamuraT.FikrigE.FlavellR. A. (1997). Interleukin (IL)-6 directs the differentiation of IL-4–producing CD4+ T cells. J. Exp. Med.185, 461–470. doi: 10.1084/jem.185.3.461
77
RinconM.IrvinC. G. (2012). Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci.8, 1281–1290. doi: 10.7150/ijbs.4874
78
RobinsonD. S.HamidQ.YingS.TsicopoulosA.BarkansJ.BentleyA. M.et al. (1992). Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med.326, 298–304. doi: 10.1056/NEJM199201303260504
79
RoubilleC.RicherV.StarninoT.McCourtC.McFarlaneA.FlemingP.et al. (2015). The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis.74, 480–489. doi: 10.1136/annrheumdis-2014-206624
80
SageA. P.MallatZ. (2017). Readapting the adaptive immune response—therapeutic strategies for atherosclerosis. Br. J. Pharmacol.174, 3926–3939. doi: 10.1111/bph.13700
81
SchanenJ. G. (2005). Asthma and incident cardiovascular disease: the atherosclerosis risk in communities study. Thorax60, 633–638. doi: 10.1136/thx.2004.026484
82
SchiefferB.SelleT.HilfikerA.Hilfiker-KleinerD.GroteK.TietgeU. J.et al. (2004). Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation110, 3493–3500. doi: 10.1161/01.CIR.0000148135.08582.97
83
SimpsonJ. L.PhippsS.BainesK. J.OreoK. M.GunawardhanaL.GibsonP. G. (2014). Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur. Respir. J.43, 1067–1076. doi: 10.1183/09031936.00105013
84
SkariaT.BurgenerJ.BachliE.SchoedonG. (2016). IL-4 causes hyperpermeability of vascular endothelial cells through Wnt5A signaling. PloS One11, e0156002. doi: 10.1371/journal.pone.0156002
85
StrandL. B.TsaiM. K.WenC. P.ChangS.-S.BrumptonB. M. (2018). Is having asthma associated with an increased risk of dying from cardiovascular disease? a prospective cohort study of 446 346 Taiwanese adults. BMJ Open8, e019992. doi: 10.1136/bmjopen-2017-019992
86
SukovichD. A.KauserK.ShirleyF. D.DelVecchioV.Halks-MillerM.RubanyiG. M. (1998). Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 18, 1498–1505 doi: 10.1161/01.ATV.18.9.1498
87
TattersallM. C.Barnet JodiH.Korcarz ClaudiaE.Hagen ErikaW.Peppard PaulE.Stein JamesH. (2016). Late-onset asthma predicts cardiovascular disease events: the wisconsin sleep cohort. J. Am. Heart Assoc.5, e003448. doi: 10.1161/JAHA.116.003448
88
ThomsonN. C.ChaudhuriR.HeaneyL. G.BucknallC.NivenR. M.BrightlingC. E.et al. (2013). Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J. Allergy Clin. Immunol.131, 1008–1016. doi: 10.1016/j.jaci.2012.12.1574
89
ToT.StanojevicS.MooresG.GershonA. S.BatemanE. D.CruzA. A.et al. (2012). Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health12, 204. doi: 10.1186/1471-2458-12-204
90
TsengC.-H.ChenJ.-H.LinC.-L.KaoC.-H. (2015). Risk relation between rhinitis and acute ischemic stroke. Allergy Asthma Proc.36, e106–e112. doi: 10.2500/aap.2015.36.3891
91
TuletaI.SkowaschD.AurichF.EcksteinN.SchuelerR.PizarroC.et al. (2017). Asthma is associated with atherosclerotic artery changes. PloS One12, e0186820. doi: 10.1371/journal.pone.0186820
92
VijayakumarJ.SubramanianS.SinghP.CorsiniE.FontanezS.LawlerM.et al. (2013). Arterial inflammation in bronchial asthma. J. Nucl. Cardiol. Off. Publ. Am. Soc. Nucl. Cardiol.20, 385–395. doi: 10.1007/s12350-013-9697-z
93
WangL.GaoS.XuW.ZhaoS.ZhouJ.WangN.et al. (2014). Allergic asthma accelerates atherosclerosis dependent on Th2 and Th17 in apolipoprotein E deficient mice. J. Mol. Cell Cardiol.72, 20–27. doi: 10.1016/j.yjmcc.2014.02.005
94
WelshP.GrassiaG.BothaS.SattarN.MaffiaP. (2017). Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?: targeting inflammation in CVD. Br. J. Pharmacol.174, 3898–3913. doi: 10.1111/bph.13818
95
WenzelS. E.BarnesP. J.BleeckerE. R.BousquetJ.BusseW.DahlénS.-E.et al. (2009). A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med.179, 549–558. doi: 10.1164/rccm.200809-1512OC
96
WenzelS. E. (2012). Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med.18, 716–725. doi: 10.1038/nm.2678
97
WHO. (2011). Global status report on noncommunicable diseases 2010. World Health Organization. 176.
98
WillemsS.VinkA.BotI.QuaxP. H. A.de BorstG. J.de VriesJ-PPMet al. (2013). Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur. Heart J.34, 3699–3706. doi: 10.1093/eurheartj/eht186
99
WongC. K.HoC. Y.KoF. W. S.ChanC. H. S.HoA. S. S.HuiD. S. C.et al. (2001). Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin. Exp. Immunol.125, 177–183. doi: 10.1046/j.1365-2249.2001.01602.x
100
YehJ.-J.SyueS.-H.LinC.-L.HsuC. Y.ShaeZ.KaoC.-H. (2019). Statin use and vital organ failure in patients with asthma–chronic obstructive pulmonary disease overlap: a time-dependent population-based study. Front. Pharmacol.10, 889. doi: 10.3389/fphar.2019.00889
101
YildizP.OflazH.CineN.GenchallacH.Erginel-ÜnaltunaN.YildizA.et al. (2004). Endothelial dysfunction in patients with asthma: the role of polymorphisms of ACE and endothelial NOS genes. J. Asthma41, 159–166. doi: 10.1081/JAS-120026073
102
YoonA. M. C.ChiuV.RanaJ. S.SheikhJ. (2016). Association of allergic rhinitis, coronary heart disease, cerebrovascular disease, and all-cause mortality. Ann. Allergy Asthma Immunol.117, 359–364.e1. doi: 10.1016/j.anai.2016.08.021
103
ZhangW.TangT.NieD.WenS.JiaC.ZhuZ.et al. (2015). IL-9 aggravates the development of atherosclerosis in ApoE–/– mice. Cardiovasc. Res.106, 453–464. doi: 10.1093/cvr/cvv110
104
ZhouY.McLaneM.LevittR. C. (2001). Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir. Res.2, 80–84. doi: 10.1186/rr42
105
ZhuM.LiangZ.WangT.ChenR.WangG.JiY. (2016). Th1/Th2/Th17 cells imbalance in patients with asthma with and without psychological symptoms. Allergy Asthma Proc.37, 148–156. doi: 10.2500/aap.2016.37.3928
106
ZieglerL.GajulapuriA.FrumentoP.BonomiA.WallénH.de FaireU.et al. (2019). Interleukin 6 trans-signalling and risk of future cardiovascular events. Cardiovasc. Res.115, 213–221. doi: 10.1093/cvr/cvy191
Summary
Keywords
asthma, atherosclerosis, cardiovascular disease, cytokines, interleukin
Citation
Gurgone D, McShane L, McSharry C, Guzik TJ and Maffia P (2020) Cytokines at the Interplay Between Asthma and Atherosclerosis?. Front. Pharmacol. 11:166. doi: 10.3389/fphar.2020.00166
Received
20 September 2019
Accepted
07 February 2020
Published
04 March 2020
Volume
11 - 2020
Edited by
Jesmond Dalli, Queen Mary University of London, United Kingdom
Reviewed by
Kian Fan Chung, Imperial College London, United Kingdom; Grzegorz Woszczek, King's College London, United Kingdom
Updates
Copyright
© 2020 Gurgone, McShane, McSharry, Guzik and Maffia.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pasquale Maffia, Pasquale.Maffia@glasgow.ac.uk
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.